Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

BioVaxys Technology Corp. C.BIOV

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, whi...

Latest News

BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D


BioVaxys Technology Corp. Closes Debt Settlement Transaction


BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement


CSE Bulletin: MOC Eligibility Update


BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M


BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES


BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES


BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS


BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data...


BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS


BIOVAXYS ANNOUNCES LIFE OFFERING


BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA"...


BIOVAXYS ANNOUNCES CLOSING OF UNSECURED CONVERTIBLE DEBENTURE OFFERING


CSE Bulletin: Consolidation - BioVaxys Technology Corp. (BIOV)


BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE